JGCM
EW icon

Joseph Group Capital Management’s Edwards Lifesciences EW Stock Holding History

Joseph Group Capital Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.1K Buy
189
+120
+174% +$9.89K ﹤0.01% 219
2025
Q4 		$5.88K Buy
+69
New +$5.66K ﹤0.01% 249

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Joseph Group Capital Management's EW Position: Q1 2026 in Review

Joseph Group Capital Management increased its Edwards Lifesciences (EW) stake by 174% in Q1 2026, buying an estimated $9.89K and bringing the position to 189 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #219.

Joseph Group Capital Management first reported a position in EW in Q4 2025 and has held it in 2 quarters since. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Joseph Group Capital Management held 189 shares of Edwards Lifesciences worth $15.1K as of Q1 2026.
  • Joseph Group Capital Management bought 120 Edwards Lifesciences shares in Q1 2026, an estimated $9.89K.
  • Edwards Lifesciences made up ﹤0.01% of Joseph Group Capital Management's portfolio in Q1 2026, its #219 holding.
  • Joseph Group Capital Management first reported a position in Edwards Lifesciences in Q4 2025 and has held it in 2 quarters since.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Joseph Group Capital Management's 13F filing for Q1 2026, filed 8 May 2026.